Table 1

Patient characteristics

CharacteristicOverall, n=10
Age at onset of irHepatitis, median (range)64.5 years (32–86)
Gender distribution, patients
 Male6
 Female4
Therapy at onset of irHepatitis, patients
 Anti-PD1+anti-CTLA4 (ipilimumab/nivolumab)6
 Anti-PD11
 Anti-PD1+anti-CTLA4+anti-TIGIT1
 Anti-PD1+anti-LAG3+IDO1 inhibitor1
 Anti-PDL1+vemurafenib/cobimetinib1
Treatment line, patients
 First7
 Second2
 Third and more1
Liver metastasis at onset of irHepatitis, n3
Grade of irHepatitis at infliximab, patients
 Grade 35
 Grade 45
Other irAEs preceding irHepatitis, patients
 No8
 Yes2
Other irAEs during irHepatitis, n
 No2
 Yes8
 1 irAE5
 ≥2 irAEs3
  • irAE, immune-related adverse event; irHepatitis, immune-related hepatitis.